Roche Drug Combination Shows No Added Benefit in Study

December 19, 2014 9:44 AM

6 0

Roche Drug Combination Shows No Added Benefit in Study

Roche Holding AG (ROG) reported disappointing results from a study that combined two of its newer drugs for breast cancer, denting the company’s hopes of broadening the market for treatments that are already among its fastest growing. Roche shares slumped the most in more than five years.

Patients who got a combination of Kadcyla and Perjeta lived without their disease worsening for a similar amount of time as those who got Kadcyla alone, or those receiving the older medicine Herceptin plus chemotherapy, the Basel, Switzerland-based company said in a statement today. The study, dubbe...

Read more

To category page

Loading...